Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Arthritis & Rheumatism

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ART.20858PMID 15693003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Costimulation Blockade in the Treatment of Rheumatic Diseases

  2012cited by this paper
• 30 – SYSTEMIC LUPUS ERYTHEMATOSUS AND THE KIDNEY

  2004cited by this paper
• Breaking Tolerance to Double Stranded DNA, Nucleosome, and Other Nuclear Antigens Is Not Required for the Pathogenesis of Lupus Glomerulonephritis

  2004cited by this paper
• Faculty Opinions recommendation of Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice.

  2004cited by this paper
• 2 – OVERVIEW OF CELLULAR IMMUNE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS

  2004cited by this paper
• Differential antibody recognition of the 349–364aa B-cell epitope of human La/SSB protein and its phosphorylated analogue

  2004cited by this paper
• Regulatory lymphocytes: Regulatory T cells under scrutiny

  2003cited by this paper
• Therapeutic CD154 antibody for lupus: promise for the future?

  2003cited by this paper
• Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

  2003cited by this paper
• B lymphocytes and systemic lupus erythematosus

  2003cited by this paper
• Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

  2003cited by this paper
• Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

  2003cited by this paper
• Remission of refractory lupus nephritis with a protocol including rituximab

  2003cited by this paper
• A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

  2003cited by this paper
• The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus

  2003cited by this paper
• Efficacy and safety of rituximab in type II mixed cryoglobulinemia.

  2003cited by this paper
• Major Peptide Autoepitopes for Nucleosome‐Centered T and B Cell Interaction in Human and Murine Lupus

  2003cited by this paper
• The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

  2003cited by this paper
• Recent advances in the pathogenesis of lupus nephritis: autoantibodies and B cells.

  2003cited by this paper
• Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

  2003cited by this paper
• Quantification of regulatory T cells in patients with systemic lupus erythematosus.

  2003cited by this paper
• LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

  2003cited by this paper
• Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

  2003cited by this paper
• CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition

  2002cited by this paper
• Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

  2002cited by this paper
• Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.

  2002cited by this paper
• An open study of B lymphocyte depletion in systemic lupus erythematosus.

  2002cited by this paper
• Effective B cell depletion with rituximab in the treatment of autoimmune diseases.

  2002cited by this paper
• Treatment of Waldenström's macroglobulinemia with rituximab.

  2002cited by this paper
• Treating human autoimmune disease by depleting B cells

  2002cited by this paper
• Rituximab in B‐cell disorders other than non‐Hodgkin's Iymphoma

  2002cited by this paper
• Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

  2001cited by this paper
• Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

  2001cited by this paper
• B-Cell Kinase Lyn Deficiency in Patients With Systemic Lupus Erythematosus

  2001cited by this paper
• Apoptosis and Altered Dendritic Cell Homeostasis in Lupus Nephritis Are Limited by Anti-CD154 Treatment

  2001cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• Immunoglobulin variable-region gene usage in systemic autoimmune diseases.

  2001cited by this paper
• Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus

  2001cited by this paper
• Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis

  2000cited by this paper
• Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide.

  2000cited by this paper
• Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

  2000cited by this paper
• The central and multiple roles of B cells in lupus pathogenesis

  1999cited by this paper
• A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-independent Role for B Cells in Murine Lupus

  1999cited by this paper
• Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.

  1999cited by this paper
• B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.

  1999cited by this paper
• A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance.

  1998cited by this paper
• Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

  1998cited by this paper
• A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice.

  1998cited by this paper
• Antibodies to DNA.

  1998cited by this paper
• Flow cytometric quantitation of yeast a novel technique for use in animal model work and in vitro immunologic assays.

  1998cited by this paper
• Participation of the CD69 Antigen in the T‐Cell Activation Process of Patients with Systemic Lupus Erythematosus

  1998cited by this paper
• Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production.

  1996cited by this paper
• Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

  1996cited by this paper
• B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events.

  1996cited by this paper
• CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis.

  1995cited by this paper
• Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy

  1993cited by this paper
• Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

  1992cited by this paper
• Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c.

  1992cited by this paper
• Induction of autoreactive B cells allows priming of autoreactive T cells

  1991cited by this paper
• Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization.

  1987cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper

• Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study

  2025cites this paper
• Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications

  2025cites this paper
• Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report

  2025cites this paper
• Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

  2025cites this paper
• A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis.

  2024cites this paper
• New sights into new‐onset and relapsed minimal change disease post COVID‐19 vaccination: A systemic review of the clinical characteristics and underlying pathogenesis

  2024cites this paper
• Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis

  2024cites this paper
• Rituximab in the Treatment of Non-Infectious Uveitis: A Review

  2024cites this paper
• Rituximab use and the increased risk of reactivation of latent tuberculosis?

  2024cites this paper
• Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review.

  2024cites this paper
• Lactobacillus plantarum CQPC02 intervenes in mouse lupus nephritis by regulating the NF-κB signaling pathway

  2023cites this paper
• Therapeutic approach to the lung-kidney syndrome associated with systemic lupus erythematosus, a medical emergency that is a challenge for the clinician

  2023cites this paper
• Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities

  2023cites this paper
• CAR T Cell Therapy: A New Hope for Refractory Lupus?

  2023cites this paper
• Effects of Lactobacillus plantarum HFY15 on Lupus Nephritis in Mice by Regulation of the TGF-β1 Signaling Pathway

  2022cites this paper
• Off-Label Uses of Rituximab in Dermatology

  2022cites this paper
• B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab

  2022cites this paper
• Rituximab Dosing in Glomerular Diseases: A Scoping Review

  2022cites this paper
• Effect of Rituximab on 24-Hour Urine Protein and Albumin or Renal Function in Patients with Glomerulonephritis

  2022cites this paper
• Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis

  2022cites this paper
• Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

  2022cites this paper
• Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch

  2022cites this paper
• Rituximab May Have Positive Effect on Refractory Nephrotic Syndrome: A Meta-Analysis of Randomized Trials

  2022cites this paper
• B cell phenotype, activity, and function in idiopathic nephrotic syndrome

  2022cites this paper
• Rituximab therapy for lupus nephritis: A meta‑analysis

  2021cites this paper
• Hepatitis E Virus Infection—Immune Responses to an Underestimated Global Threat

  2021cites this paper
• Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases

  2021cites this paper
• Repositioning drugs for systemic lupus erythematosus

  2021cites this paper
• Weighted Gene Co-expression Network Analysis Reveals Different Immunity but Shared Renal Pathology Between IgA Nephropathy and Lupus Nephritis

  2021cites this paper
• B Lineage Cells in ANCA-Associated Vasculitis

  2021cites this paper
• B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab

  2021cites this paper
• Abordaje terapéutico del síndrome pulmón-riñón asociado con lupus eritematoso sistémico, una urgencia médica que es un reto para el clínico

  2021cites this paper
• Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis

  2020cites this paper
• Rituximab in treatment of collapsing FSGS—A case series

  2020cites this paper
• Rituximab use as induction therapy for lupus nephritis: a systematic review

  2020cites this paper
• Effects of rituximab therapy on B cell differentiation and depletion

  2020cites this paper
• Clinical efficacy and safety of rituximab in lupus nephritis

  2019cites this paper
• Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

  2019cites this paper
• Preformed donor‐reactive T cells that persist after ABO desensitization predict severe T cell‐mediated rejection after living donor kidney transplantation – a retrospective study

  2019cites this paper
• B Cell Biology and Related Therapies in SLE

  2019cites this paper
• Modifying Graft-versus-Host Disease in a Humanized Mouse Model by Targeting Macrophages or B-Cells

  2019cites this paper
• Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases

  2019cites this paper
• (2016). Cell biology and genetics of minimal change disease. F1000Research , 5 .

  2019cites this paper
• Autoimmune Sequelae Following Rituximab Therapy: A Review of the Literature and Potential Immunologic Mechanisms

  2018cites this paper
• EVIEW ituximab in dermatology

  2018cites this paper
• Promising Treatment Alternatives

  2018cites this paper
• Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion

  2018cites this paper
• Targeted Therapies for Autoimmune Bullous Diseases: Current Status

  2018cites this paper
• Kobe University Repository : Kernel タイトル Tit le Rituximab treatment for posttransplant lymphoproliferat ive disorder ( PTLD ) induces complete remission of recurrent nephrot ic syndrome

  2018cites this paper
• Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience

  2018cites this paper
• Neuropsychiatric Systemic Lupus Erythematosus

  2018cites this paper
• Rituximab in Minimal Change Disease

  2017cites this paper
• Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

  2017cites this paper
• Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy

  2017cites this paper
• ituximab in dermatology

  2017cites this paper
• A comprehensive evaluation for the treatment of lupus nephritis.

  2017cites this paper
• Efficacy of Rituximab in a Systemic Lupus Erythematosus Patient Presenting with Diffuse Alveolar Hemorrhage

  2017cites this paper
• Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions.

  2017cites this paper
• Regulatory T cells in immune‐mediated renal disease

  2016cites this paper
• Efficient Culture of Human Naive and Memory B Cells for Use as APCs

  2016cites this paper
• Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab

  2016cites this paper
• CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients

  2016influential citation
• The Role of TLR4 on B Cell Activation and Anti-β 2GPI Antibody Production in the Antiphospholipid Syndrome

  2016cites this paper
• A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

  2016cites this paper
• Rethinking biologics in lupus nephritis

  2016cites this paper
• Cell biology and genetics of minimal change disease

  2016cites this paper
• Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients

  2016cites this paper
• Current role of rituximab in systemic lupus erythematosus

  2015cites this paper
• The expression of Fcγ receptors in Hashimoto's thyroiditis.

  2015cites this paper
• Renal Involvement in Children with Systemic Lupus Erythematosus

  2015cites this paper
• Personalized Treatment Options in Dermatology

  2015cites this paper
• Update on the management of lupus nephritis

  2015cites this paper
• Immune Renal Injury: Similarities and Differences Between Glomerular Diseases and Transplantation

  2015cites this paper
• Effect of Pretransplant Rituximab Use on Posttransplant Clinical Outcomes in Patients with High Panel Reactive Antibody Scores

  2015cites this paper
• A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment.

  2015cites this paper
• Regulatory B cells mediate tolerance to apoptotic self in health: implications for disease.

  2015cites this paper
• The role of rituximab in adults with warm antibody autoimmune hemolytic anemia.

  2015cites this paper
• Bullous Diseases: Old Blisters with New Therapeutic Targets

  2015cites this paper
• ABO desensitization affects cellular immunity and infection control after renal transplantation

  2015cites this paper
• BLyS and APRIL Cytokines as Biomarkers of Kidney Diseases

  2015cites this paper
• B lymphocytes in Autoimmune Rheumatic Diseases: Pathogenesis to Treatment

  2015cites this paper
• Update on B-cell targeted therapies for systemic lupus erythematosus

  2014cites this paper
• ESTUDIO MULTICÉNTRICO LONGITUDINAL DE DEPLECIÓN DE LINFOCITOS B EN LUPUS ERITEMATOSO SISTÉMICO REFRACTARIO: ESTUDIO LESIMAB

  2014influential citation
• [Rituximab for the treatment of nephrotic syndrome].

  2014cites this paper
• Rituximab and Lupus – A Promising Pair?

  2014cites this paper
• Molecular targeted therapy against B cells in multiple sclerosis

  2014cites this paper
• Apoptotic B cells: their interactions with macrophages and modulation by rituximab

  2014cites this paper
• Rationale for B cell targeting in SLE

  2014cites this paper
• Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?

  2014cites this paper
• Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.

  2014cites this paper
• Rituximab Treatment for Nephrotic Syndrome in Children

  2014cites this paper
• Emerging biological therapies for systemic lupus erythematosus

  2014cites this paper
• Pharmacological Effects and Mechanisms of Action of Agents Blocking B Cells

  2014cites this paper
• CD19 and CD32b Differentially Regulate Human B Cell Responsiveness

  2014cites this paper
• This information is current as Human B Cell Responsiveness CD 19 and CD 32 b Differentially Regulate

  2014cites this paper
• [Is rituximab effective for induction of remission in lupus nephritis?].

  2014cites this paper
• Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first.

  2014cites this paper
• Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.

  2014cites this paper
• Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

  2014cites this paper
• Rituximab in dermatology.

  2013cites this paper